15-05-2025
Chardan Capital Reaffirms Their Buy Rating on Passage Bio (PASG)
In a report released yesterday, Geulah Livshits from Chardan Capital maintained a Buy rating on Passage Bio (PASG – Research Report), with a price target of $6.00. The company's shares closed yesterday at $0.27.
Confident Investing Starts Here:
Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Livshits is a 5-star analyst with an average return of 16.2% and a 37.68% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Solid Biosciences, and Passage Bio.
Passage Bio has an analyst consensus of Strong Buy, with a price target consensus of $7.33.
Based on Passage Bio's latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $15.41 million. In comparison, last year the company had a GAAP net loss of $16.71 million
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PASG in relation to earlier this year. Last month, Orbimed Advisors Llc, a Major Shareholder at PASG sold 149,054.00 shares for a total of $49,704.12.
